Nasdaq

BioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO® (berotralstat)

– Additional analysis from APeX-S showed patients who self-reported HAE attack rates at baseline had a median attack rate of 0 attacks per month across 12-month period – RESEARCH TRIANGLE PARK, N.C., ...
Nasdaq

BioCryst Pharmaceuticals Reports Significant Reductions in HAE Attack Rates with ORLADEYO® in New Real-World Evidence Presentations at ISPOR 2025

BioCryst Pharmaceuticals, Inc. has released new real-world evidence demonstrating significant and sustained reductions in Hereditary Angioedema (HAE) attack rates in adolescents and individuals with ...